5 Biotech Stocks with Huge Potential

4. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 39

Cambridge, Massachusetts-based Moderna, Inc. (NASDAQ:MRNA) is a leading biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. In addition to the commercial stage covid19 vaccine, the clinical pipeline of the company includes therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

On December 11, Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE: MRK) announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy, in combination with Merck’s KEYTRUDA, as adjuvant treatment in patients with certain types of resected non-small cell lung cancer.

Moderna, Inc. (NASDAQ:MRNA) shares were owned by 37 leading hedge funds with the total shares held by them valued at nearly $1.4 billion, as of Q4 2023. Patrick Degorce’s Theleme Partners was the lead hedge fund shareholder with ownership of 7.3 million shares valued at $731 million.